4 transcripts
MLYS
Earnings call transcript
NASDAQ
2024 Q2
13 Aug 24
benefit.
Moving to Launch-HTN, which is our second pivotal trial that was initiated in the fourth quarter of 2023, we are pleased to announce
MLYS
Earnings call transcript
NASDAQ
2024 Q1
9 May 24
approach with lorundrostat. We believe lorundrostat has the potential to benefit millions of patients who are impacted by hypertension, kidney disease
MLYS
Earnings call transcript
NASDAQ
2023 Q4
21 Mar 24
targeted treatment approach that has the potential to benefit millions of patients who are impacted by hypertension, kidney disease and heart disease
MLYS
Earnings call transcript
NASDAQ
2023 Q2
7 Aug 23
clinical benefit for many of these patients given the role that abnormally elevated aldosterone plays in the progression of this disease. Let me now turn
- Prev
- 1
- Next